Exclusive: CellCentric collects $120M to treat multiple myeloma with a capsule

Kyle LaHucik

Senior Reporter

CellCentric has raised a $120 million Series C round to support a potential accelerated approval in multiple myeloma, the UK biotech exclusively told Endpoints News …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Exclusive: CellCentric collects $120M to treat multiple myeloma with a capsule

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Regeneron plans to buy 23andMe for $256M

Apnimed posts first set of Phase 3 sleep apnea results, aims for approval filing in 2026

FDA approves Novavax's Covid vaccine after six-week delay, but for a smaller population

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Lower attendance at cell and gene therapy conference mirrors challenged industry

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Ex­clu­sive: Cell­Cen­tric col­lects $120M to treat mul­ti­ple myelo­ma with a cap­sule

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Exclusive: CellCentric collects $120M to treat multiple myeloma with a capsule